Seema Naik, MD
Hematology & Oncology · Hershey, PANPI 1245460575
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $12,762 of the $15,044 with a category attached, or 84.8%. 18 manufacturers reported payments, led by Sanofi at 31.5% of the total. Reporting peaked in 2019 at $6,662 and has fallen 91.0% since, to $600 in 2025.
Across 44 payments — averaging $341.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$5K
- ADC Therapeutics America, Inc.$2K
- Gilead$2K
- Takeda Pharmaceuticals U.S.A., Inc.$2K
- Johnson & Johnson$2K
- Bristol Myers Squibb$1K
- plus $1K from 12 others
Across 179 payments — averaging $6729.88 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$444K
- Genentech, Inc.$435K
- Beone Medicines Ltd.$134K
- Janssen Research & Development, LLC$72K
- Takeda Pharmaceuticals U.S.A., Inc.$52K
- Beone Medicines USA, Inc.$34K
- plus $33K from 4 others
What the payments were for
- Consulting fees$12,76285%
- Food & beverage$1,60411%
- Education$6775%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 1 | $4,732 |
| ADC Therapeutics America, Inc. | 1 | $2,400 |
| Gilead | 15 | $1,959 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $1,650 |
| Johnson & Johnson | 5 | $1,638 |
| Bristol Myers Squibb | 1 | $1,350 |
| AstraZeneca(2 entities) | 6 | $354 |
| Jazz Pharmaceuticals Inc. | 2 | $162 |
| Seagen Inc. | 2 | $129 |
| Novartis | 2 | $116 |
| Incyte Corporation | 1 | $110 |
| E.r. Squibb & Sons, L.L.C. | 1 | $100 |
| Amgen | 1 | $92 |
| AbbVie | 1 | $91 |
| Janssen Scientific Affairs, LLC | 1 | $85 |
| Janssen Global Services, LLC | 1 | $28 |
| Daiichi Sankyo Inc. | 1 | $25 |
| EMD Serono, Inc. | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,044 in reported general payments places this provider in the 80th percentile of 682 hematology & oncology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PomalystPomalidomide | 45 | $1,008,331 |
| Lenalidomide | 47 | $726,468 |
| NinlaroIxazomib Citrate | 45 | $585,059 |
| BrukinsaZanubrutinib | 39 | $577,228 |
| RevlimidLenalidomide | 26 | $453,638 |
| CalquenceAcalabrutinib Maleate | 29 | $431,675 |
| JaypircaPirtobrutinib | 28 | $431,589 |
| RezurockBelumosudil Mesylate | 13 | $284,553 |
| IclusigPonatinib Hcl | 12 | $260,709 |
| JakafiRuxolitinib Phosphate | 16 | $231,709 |
| ImbruvicaIbrutinib | 13 | $212,243 |
| EliquisApixaban | 60 | $37,480 |
| Atovaquone | 33 | $9,995 |
| ValacyclovirValacyclovir Hcl | 100 | $4,765 |
| Acyclovir | 151 | $3,071 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Pomalyst | $100 | $1,008,33145 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Ninlaro, Iclusig | $1,650 | $845,76757 claims |
| Bristol Myers SquibbRevlimid | $1,350 | $453,63826 claims |
| AstraZenecaCalquence | $354 | $431,67529 claims |
| Incyte CorporationJakafi | $110 | $231,70916 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 682 hematology & oncology providers in Pennsylvania.
Other hematology & oncology in Hershey
- Kevin RakszawskiHershey$237K
- Chandra BelaniHershey$149K
- Jeffrey PuHershey$103K
- Cristina TruicaHershey$102K
- David NguyenHershey$81K
- Joseph DrabickHershey$53K
- Patrick MaHershey$42K
- Salman FazalPittsburgh$2.3M
- Cyrus KhanPittsburgh$1.9M
- Usama GergisAllentown$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.